1
|
Zhang Y, Whaley-Connell AT, Sowers JR, Ren J. Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. Pharmacol Ther 2018; 191:1-22. [PMID: 29909238 PMCID: PMC6195437 DOI: 10.1016/j.pharmthera.2018.06.004] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 06/05/2018] [Indexed: 12/16/2022]
Abstract
Although advances in medical technology and health care have improved the early diagnosis and management for cardiorenal metabolic disorders, the prevalence of obesity, insulin resistance, diabetes, hypertension, dyslipidemia, and kidney disease remains high. Findings from numerous population-based studies, clinical trials, and experimental evidence have consolidated a number of theories for the pathogenesis of cardiorenal metabolic anomalies including resistance to the metabolic action of insulin, abnormal glucose and lipid metabolism, oxidative and nitrosative stress, endoplasmic reticulum (ER) stress, apoptosis, mitochondrial damage, and inflammation. Accumulating evidence has recently suggested a pivotal role for proteotoxicity, the unfavorable effects of poor protein quality control, in the pathophysiology of metabolic dysregulation and related cardiovascular complications. The ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathways, two major although distinct cellular clearance machineries, govern protein quality control by degradation and clearance of long-lived or damaged proteins and organelles. Ample evidence has depicted an important role for protein quality control, particularly autophagy, in the maintenance of metabolic homeostasis. To this end, autophagy offers promising targets for novel strategies to prevent and treat cardiorenal metabolic diseases. Targeting autophagy using pharmacological or natural agents exhibits exciting new strategies for the growing problem of cardiorenal metabolic disorders.
Collapse
Affiliation(s)
- Yingmei Zhang
- Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071, USA.
| | - Adam T Whaley-Connell
- Research Service, Harry S Truman Memorial Veterans' Hospital, University of Missouri-Columbia School of Medicine, Columbia, MO, USA; Diabetes and Cardiovascular Center, Department of Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO, USA
| | - James R Sowers
- Research Service, Harry S Truman Memorial Veterans' Hospital, University of Missouri-Columbia School of Medicine, Columbia, MO, USA; Diabetes and Cardiovascular Center, Department of Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO, USA
| | - Jun Ren
- Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071, USA.
| |
Collapse
|
2
|
Mughal W, Martens M, Field J, Chapman D, Huang J, Rattan S, Hai Y, Cheung KG, Kereliuk S, West AR, Cole LK, Hatch GM, Diehl-Jones W, Keijzer R, Dolinsky VW, Dixon IM, Parmacek MS, Gordon JW. Myocardin regulates mitochondrial calcium homeostasis and prevents permeability transition. Cell Death Differ 2018; 25:1732-1748. [PMID: 29511336 PMCID: PMC6180099 DOI: 10.1038/s41418-018-0073-z] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 12/17/2017] [Accepted: 01/15/2018] [Indexed: 01/20/2023] Open
Abstract
Myocardin is a transcriptional co-activator required for cardiovascular development, but also promotes cardiomyocyte survival through an unclear molecular mechanism. Mitochondrial permeability transition is implicated in necrosis, while pore closure is required for mitochondrial maturation during cardiac development. We show that loss of myocardin function leads to subendocardial necrosis at E9.5, concurrent with elevated expression of the death gene Nix. Mechanistically, we demonstrate that myocardin knockdown reduces microRNA-133a levels to allow Nix accumulation, leading to mitochondrial permeability transition, reduced mitochondrial respiration, and necrosis. Myocardin knockdown elicits calcium release from the endo/sarcoplasmic reticulum with mitochondrial calcium accumulation, while restoration of microRNA-133a function, or knockdown of Nix rescues calcium perturbations. We observed reduced myocardin and elevated Nix expression within the infarct border-zone following coronary ligation. These findings identify a myocardin-regulated pathway that maintains calcium homeostasis and mitochondrial function during development, and is attenuated during ischemic heart disease. Given the diverse role of Nix and microRNA-133a, these findings may have broader implications to metabolic disease and cancer.
Collapse
Affiliation(s)
- Wajihah Mughal
- Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada.,Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
| | - Matthew Martens
- Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada.,Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
| | - Jared Field
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Biological Science, University of Manitoba, Winnipeg, MB, Canada
| | - Donald Chapman
- Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada.,Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
| | - Jianhe Huang
- Department of Medicine, Penn Cardiovascular Institute, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
| | - Sunil Rattan
- Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB, Canada.,Institute of Cardiovascular Sciences, St. Boniface Research Centre, Winnipeg, MB, Canada
| | - Yan Hai
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,College of Nursing, University of Manitoba, Winnipeg, MB, Canada
| | - Kyle G Cheung
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada
| | - Stephanie Kereliuk
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada
| | - Adrian R West
- Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB, Canada.,The Biology of Breathing Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
| | - Laura K Cole
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada
| | - Grant M Hatch
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada
| | - William Diehl-Jones
- Department of Biological Science, University of Manitoba, Winnipeg, MB, Canada.,Faculty of Health Disciplines, Athabasca University, Edmonton, MB, Canada
| | - Richard Keijzer
- Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB, Canada.,The Biology of Breathing Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Surgery, University of Manitoba, Winnipeg, MB, Canada
| | - Vernon W Dolinsky
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada
| | - Ian M Dixon
- Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB, Canada.,Institute of Cardiovascular Sciences, St. Boniface Research Centre, Winnipeg, MB, Canada
| | - Michael S Parmacek
- Department of Medicine, Penn Cardiovascular Institute, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
| | - Joseph W Gordon
- Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada. .,Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada. .,College of Nursing, University of Manitoba, Winnipeg, MB, Canada.
| |
Collapse
|
3
|
Zhang W, Chen C, Wang J, Liu L, He Y, Chen Q. Mitophagy in Cardiomyocytes and in Platelets: A Major Mechanism of Cardioprotection Against Ischemia/Reperfusion Injury. Physiology (Bethesda) 2018; 33:86-98. [DOI: 10.1152/physiol.00030.2017] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Mitophagy, a process that selectively removes damaged organelles by autolysosomal degradation, is an early cellular response to ischemia. Mitophagy is activated in both cardiomyocytes and platelets during ischemia/reperfusion (I/R) and heart disease conditions. We focus on the molecular regulation of mitophagy and highlight the role of mitophagy in cardioprotection.
Collapse
Affiliation(s)
- Weilin Zhang
- The State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| | - Chuyan Chen
- Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China
| | - Jun Wang
- The State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| | - Lei Liu
- The State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| | - Yubin He
- Department of Cardiology, Heart Center, Chinese Army General Hospital, Beijing, China
| | - Quan Chen
- The State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
4
|
Abstract
Cardiac stress can induce morphological, structural and functional changes of the heart, referred to as cardiac remodeling. Myocardial infarction or sustained overload as a result of pathological causes such as hypertension or valve insufficiency may result in progressive remodeling and finally lead to heart failure (HF). Whereas pathological and physiological (exercise, pregnancy) overload both stimulate cardiomyocyte growth (hypertrophy), only pathological remodeling is characterized by increased deposition of extracellular matrix proteins, termed fibrosis, and loss of cardiomyocytes by necrosis, apoptosis and/or phagocytosis. HF is strongly associated with age, and cardiomyocyte loss and fibrosis are typical signs of the aging heart. Fibrosis results in stiffening of the heart, conductivity problems and reduced oxygen diffusion, and is associated with diminished ventricular function and arrhythmias. As a consequence, the workload of cardiomyocytes in the fibrotic heart is further augmented, whereas the physiological environment is becoming less favorable. This causes additional cardiomyocyte death and replacement of lost cardiomyocytes by fibrotic material, generating a vicious cycle of further decline of cardiac function. Breaking this fibrosis-cell death axis could halt further pathological and age-related cardiac regression and potentially reverse remodeling. In this review, we will describe the interaction between cardiac fibrosis, cardiomyocyte hypertrophy and cell death, and discuss potential strategies for tackling progressive cardiac remodeling and HF.
Collapse
Affiliation(s)
- A Piek
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands
| | - R A de Boer
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands
| | - H H W Silljé
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
| |
Collapse
|
5
|
Pereg D, Cohen K, Mosseri M, Berlin T, Steinberg DM, Ellis M, Ashur-Fabian O. Incidence and Expression of Circulating Cell Free p53-Related Genes in Acute Myocardial Infarction Patients. J Atheroscler Thromb 2015; 22:981-98. [PMID: 25958931 DOI: 10.5551/jat.29223] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
AIM The circulating RNA levels are predictive markers in several diseases. We determined the levels of circulating p53-related genes in patients with acute ST-segment elevation myocardial infarction (STEMI), indicating major heart muscle damage. METHODS Plasma RNA was extracted from the patients (n=45) upon their arrival to the hospital (STEMI 0h) and at four hours post-catheterization (STEMI 4h) as well as from controls (n=34). RESULTS Of 18 circulating p53-related genes, nine genes were detectable. A significantly lower incidence of circulating p21 (p < 0.0001), Notch1 (p=0.042) and BTG2 (p < 0.0001) was observed in the STEMI 0h samples in comparison to the STEMI 4h and control samples. Lower expression levels (2.1-fold) of circulating BNIP3L (p=0.011), p21 (3.4-fold, p=0.005) and BTG2 (6.3-fold, p=0.0001) were observed in the STEMI 0h samples in comparison to the STEMI 4h samples, with a 7.4-fold lower BTG2 expression (p < 0.001) and 2.6-fold lower p21 expression (p=0.034) compared to the control samples. Moreover, the BNIP3L expression (borderline significance, p=0.0655) predicted the level of peak troponin, a marker of myocardial infarction. In addition, the BNIP3L levels on admission (p=0.0025), at post-catheterization (p=0.020) and the change between the groups (p=0.0079) were inversely associated with troponin. The BNIP3L (p=0.0139) and p21 levels (p=0.0447) were also associated with a longer time to catheterization. CONCLUSIONS Our results suggest that circulating downstream targets of p53 are inhibited during severe AMI and subsequently re-expressed after catheterization, uncovering possible novel death-or-survival decisions regarding the fate of p53 in the heart and the potential use of its target genes as prognostic biomarkers for oxygenation normalization.
Collapse
|
6
|
Biala AK, Dhingra R, Kirshenbaum LA. Mitochondrial dynamics: Orchestrating the journey to advanced age. J Mol Cell Cardiol 2015; 83:37-43. [PMID: 25918048 DOI: 10.1016/j.yjmcc.2015.04.015] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Revised: 03/30/2015] [Accepted: 04/19/2015] [Indexed: 12/20/2022]
Abstract
Aging is a degenerative process that unfortunately is an inevitable part of life and risk factor for cardiovascular disease including heart failure. Among the several theories purported to explain the effects of age on cardiac dysfunction, the mitochondrion has emerged a central regulator of this process. Hence, it is not surprising that abnormalities in mitochondrial quality control including biogenesis and turnover have such detrimental effects on cardiac function. In fact mitochondria serve as a conduit for biological signals for apoptosis, necrosis and autophagy respectively. The removal of damaged mitochondria by autophagy/mitophagy is essential for mitochondrial quality control and cardiac homeostasis. Defects in mitochondrial dynamism fission/fusion events have been linked to cardiac senescence and heart failure. In this review we discuss the impact of aging on mitochondrial dynamics and senescence on cardiovascular health. This article is part of a Special Issue entitled: CV Aging.
Collapse
Affiliation(s)
- Agnieszka K Biala
- The Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre, Winnipeg, Manitoba R2H 2A6, Canada; Department of Physiology, Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada; Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada
| | - Rimpy Dhingra
- The Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre, Winnipeg, Manitoba R2H 2A6, Canada; Department of Physiology, Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada; Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada
| | - Lorrie A Kirshenbaum
- The Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre, Winnipeg, Manitoba R2H 2A6, Canada; Department of Physiology, Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada; Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada.
| |
Collapse
|
7
|
Biala AK, Kirshenbaum LA. The interplay between cell death signaling pathways in the heart. Trends Cardiovasc Med 2014; 24:325-31. [PMID: 25263458 DOI: 10.1016/j.tcm.2014.08.002] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2014] [Revised: 08/06/2014] [Accepted: 08/07/2014] [Indexed: 01/17/2023]
Abstract
To date, one of the most intriguing and compelling concepts to impact contemporary cell biology is the notion that cell fate is "programmed" or genetically controlled. Indeed, the regulation of cell fate is crucial for embryonic development, and tissue homeostasis. Given the importance of removing damaged or irreversibly injured cells from the body, it is not surprising that defects in the regulatory mechanisms that govern cell death and/or survival more generally have been implicated in a number of human pathologies including cancer, neurodegenerative diseases, and cardiac failure. Several processes involved in the regulation of cell fate through apoptosis, necrosis, and autophagy are commonly linked through the actions of certain Bcl-2 proteins that act on the mitochondrion. For example, the Bcl-2 protein Beclin-1 is actively involved in the clearance of damaged mitochondria via mitophagy, while other Bcl-2 proteins such as Bax/Bak can initiate apoptosis or necrotic signaling pathways. The overlapping and redundant nature of these proteins highlights their evolutionary importance for regulating cardiac cell survival and death during normal and disease states. Here, we explore the interrelationship between these signaling pathways and the cellular effectors that influence cardiac cell fate.
Collapse
Affiliation(s)
- Agnieszka K Biala
- The Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre, University of Manitoba, Centre Rm. 3016, 351 TachéAvenue, Winnipeg, Manitoba, Canada R2H 2A6; Department of Physiology, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Lorrie A Kirshenbaum
- The Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre, University of Manitoba, Centre Rm. 3016, 351 TachéAvenue, Winnipeg, Manitoba, Canada R2H 2A6; Department of Physiology, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Pharmacology and Therapeutics, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
| |
Collapse
|
8
|
Pietraforte D, Vona R, Marchesi A, de Jacobis IT, Villani A, Del Principe D, Straface E. Redox control of platelet functions in physiology and pathophysiology. Antioxid Redox Signal 2014; 21:177-93. [PMID: 24597688 DOI: 10.1089/ars.2013.5532] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
SIGNIFICANCE An imbalance between the production and the detoxification of reactive oxygen species and reactive nitrogen species (ROS/RNS) can be implicated in many pathological processes. Platelets are best known as primary mediators of hemostasis and can be either targets of ROS/RNS or generate radicals during cell activation. These conditions can dramatically affect platelet physiology, leading even, as an ultimate event, to the cell number modification. In this case, pathological conditions such as thrombocytosis (promoted by increased cell number) or thrombocytopenia and myelodysplasia (promoted by cell decrease mediated by accelerated apoptosis) can occur. RECENT ADVANCES Usually, in peripheral blood, ROS/RNS production is balanced by the rate of oxidant elimination. Under this condition, platelets are in a nonadherent "resting" state. During endothelial dysfunction or under pathological conditions, ROS/RNS production increases and the platelets respond with specific biochemical and morphologic changes. Mitochondria are at the center of these processes, being able to both generate ROS/RNS, that drive redox-sensitive events, and respond to ROS/RNS-mediated changes of the cellular redox state. Irregular function of platelets and enhanced interaction with leukocytes and endothelial cells can contribute to pathogenesis of atherosclerotic and thrombotic events. CRITICAL ISSUES The relationship between oxidative stress, platelet death, and the activation-dependent pathways that drive platelet pro-coagulant activity is unclear and deserves to be explored. FUTURE DIRECTIONS Expanding knowledge about how platelets can mediate hemostasis and modulate inflammation may lead to novel and effective therapeutic strategies for the long and growing list of pathological conditions that involve both thrombosis and inflammation.
Collapse
Affiliation(s)
- Donatella Pietraforte
- 1 Department of Cell Biology and Neurosciences, Section of Cell Aging and Gender Medicine, Istituto Superiore di Sanità , Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
The field of mitochondrial ion channels has recently seen substantial progress, including the molecular identification of some of the channels. An integrative approach using genetics, electrophysiology, pharmacology, and cell biology to clarify the roles of these channels has thus become possible. It is by now clear that many of these channels are important for energy supply by the mitochondria and have a major impact on the fate of the entire cell as well. The purpose of this review is to provide an up-to-date overview of the electrophysiological properties, molecular identity, and pathophysiological functions of the mitochondrial ion channels studied so far and to highlight possible therapeutic perspectives based on current information.
Collapse
|
10
|
Mitchell A, Guan W, Staggs R, Hamel A, Hozayen S, Adhikari N, Grindle S, Desir S, John R, Hall JL, Eckman P. Identification of differentially expressed transcripts and pathways in blood one week and six months following implant of left ventricular assist devices. PLoS One 2013; 8:e77951. [PMID: 24205042 PMCID: PMC3804545 DOI: 10.1371/journal.pone.0077951] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Accepted: 09/06/2013] [Indexed: 11/19/2022] Open
Abstract
Introduction Continuous-flow left ventricular assist devices (LVADs) are an established therapy for patients with end-stage heart failure. The short- and long-term impact of these devices on peripheral blood gene expression has not been characterized, and may provide insight into the molecular pathways mediated in response to left ventricular remodeling and an improvement in overall systemic circulation. We performed RNA sequencing to identify genes and pathways influenced by these devices. Methods RNA was extracted from blood of 9 heart failure patients (8 male) prior to LVAD implantation, and at 7 and 180 days postoperatively. Libraries were sequenced on an Illumina HiSeq2000 and sequences mapped to the human Ensembl GRCh37.67 genome assembly. Results A specific set of genes involved in regulating cellular immune response, antigen presentation, and T cell activation and survival were down-regulated 7 days after LVAD placement. 6 months following LVAD placement, the expression levels of these genes were significantly increased; yet importantly, remained significantly lower than age and sex-matched samples from healthy controls. Conclusions In summary, this genomic analysis identified a significant decrease in the expression of genes that promote a healthy immune response in patients with heart failure that was partially restored 6 months following LVAD implant.
Collapse
Affiliation(s)
- Adam Mitchell
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Weihua Guan
- Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Rodney Staggs
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Aimee Hamel
- Lillehei Clinical Research Unit, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Sameh Hozayen
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Neeta Adhikari
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Suzanne Grindle
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Snider Desir
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Ranjit John
- Department of Surgery, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Jennifer L. Hall
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- * E-mail: (JH); (PE)
| | - Peter Eckman
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- * E-mail: (JH); (PE)
| |
Collapse
|
11
|
Simpson PC. Where are the new drugs to treat heart failure? Introduction to the special issue on "key signaling molecules in hypertrophy and heart failure". J Mol Cell Cardiol 2011; 51:435-7. [PMID: 21851824 DOI: 10.1016/j.yjmcc.2011.08.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2011] [Accepted: 08/10/2011] [Indexed: 12/30/2022]
|
12
|
Epigenetic regulation of E2F-1-dependent Bnip3 transcription and cell death by nuclear factor-κB and histone deacetylase-1. Pediatr Cardiol 2011; 32:263-6. [PMID: 21293853 DOI: 10.1007/s00246-011-9893-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Accepted: 01/11/2011] [Indexed: 01/26/2023]
Abstract
A delicate balance exists between cell growth and cell death. In the context of the adult myocardium, inappropriate or inordinate cell loss through an apoptotic process may profoundly influence cardiac structure, function, or both given the limited and meager ability of the heart for repair after injury. Earlier work by the authors' laboratory identified a close relation between cell cycle factor E2F-1 and hypoxia-inducible factor Bnip3 as the key regulator of apoptosis and autophagy in ventricular myocytes. Epigenetic changes by histone-modifying proteins, namely, histone deacetylases (HDACs) influence cell survival by altering the activity of histone core proteins, transcription factors, or both. This report highlights the intricate nature between the cellular factors E2F-1 and nuclear factor-κB (NF-κB) and the epigenetic regulation of Bnip3 gene transcription by HDAC1 for cell survival of ventricular myocytes.
Collapse
|